Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

  • Van Emburgh, Beth O.
  • Vidal Barrull, Joana
  • Bellosillo Paricio, Beatriz
  • Albanell Mestres, Joan
  • Montagut Viladot, Clara
  • Bardelli, Alberto
Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of these therapeutic agents. At relapse, the majority of patients develop RAS mutations, while a subset acquires EGFR extracellular domain (ECD) mutations. Here we find that patients who experience greater and longer responses to EGFR blockade preferentially develop EGFR ECD mutations, while RAS mutations emerge more frequently in patients with smaller tumour shrinkage and shorter progression-free survival. In circulating cell-free tumour DNA of patients treated with anti-EGFR antibodies, RAS mutations emerge earlier than EGFR ECD variants. Subclonal RAS but not EGFR ECD mutations are present in CRC samples obtained before exposure to EGFR blockade. These data indicate that clonal evolution of drug-resistant cells is associated with the clinical outcome of CRC patients treated with anti-EGFR antibodies, This study was supported by European Community’s Seventh Framework Programme under grant agreement no. 602901 MErCuRIC (A.B. and F.D.N.); European Community’s Seventh Framework Programme under grant agreement no. 635342-2 MoTriColor (A.B. and S.S.); TRANSCAN-2 JTC 2014 contract no. TRS-2015-00000060 INTRACOLOR (S.A.); IMI contract no. 115749 CANCER-ID (A.B.); AIRC 2010 Special Program Molecular Clinical Oncology 5 per mille, Project no. 9970 Extension program (A.B. and S.S.); Fondazione Piemontese per la Ricerca sul Cancro-ONLUS 5 per mille 2011 Ministero della Salute (A.B.); AIRC IG no. 16788 (A.B.); AIRC and the EU under a Marie Curie COFUND (G.G.); Fondo per la Ricerca Locale (ex 60%), Universita` di Torino, 2014 (F.D.N.); Instituto de Salud Carlos III, organismo adscrito al Ministerio de Economía y Competitividad and ‘Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa’ grants PI15/00457 and DTS15/00048 (C.M.); PIE15/00008 and PI15/00146 (J.A.); RETIC Cancer–Instituto de Salud Carlos III RD12/0036/0051 (C.M. and J.A.); 2014SGR740 (J.A.); and Xarxa de Banc de Tumors de Catalunya and Fundació Cellex (C.M.). Investigators at Niguarda Cancer Centers are supported by the grants Terapia Molecolare dei Tumori (A.S.-B. and S.S.) and Dynamic of Tumor Evolution & Therapy (A.S.-B.) from Fondazione Oncologia Niguarda Onlus.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

  • Van Emburgh, Beth O.
  • Vidal Barrull, Joana
  • Bellosillo Paricio, Beatriz
  • Albanell Mestres, Joan
  • Montagut Viladot, Clara
  • Bardelli, Alberto
Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of these therapeutic agents. At relapse, the majority of patients develop RAS mutations, while a subset acquires EGFR extracellular domain (ECD) mutations. Here we find that patients who experience greater and longer responses to EGFR blockade preferentially develop EGFR ECD mutations, while RAS mutations emerge more frequently in patients with smaller tumour shrinkage and shorter progression-free survival. In circulating cell-free tumour DNA of patients treated with anti-EGFR antibodies, RAS mutations emerge earlier than EGFR ECD variants. Subclonal RAS but not EGFR ECD mutations are present in CRC samples obtained before exposure to EGFR blockade. These data indicate that clonal evolution of drug-resistant cells is associated with the clinical outcome of CRC patients treated with anti-EGFR antibodies, This study was supported by European Community’s Seventh Framework Programme under grant agreement no. 602901 MErCuRIC (A.B. and F.D.N.); European Community’s Seventh Framework Programme under grant agreement no. 635342-2 MoTriColor (A.B. and S.S.); TRANSCAN-2 JTC 2014 contract no. TRS-2015-00000060 INTRACOLOR (S.A.); IMI contract no. 115749 CANCER-ID (A.B.); AIRC 2010 Special Program Molecular Clinical Oncology 5 per mille, Project no. 9970 Extension program (A.B. and S.S.); Fondazione Piemontese per la Ricerca sul Cancro-ONLUS 5 per mille 2011 Ministero della Salute (A.B.); AIRC IG no. 16788 (A.B.); AIRC and the EU under a Marie Curie COFUND (G.G.); Fondo per la Ricerca Locale (ex 60%), Universita` di Torino, 2014 (F.D.N.); Instituto de Salud Carlos III, organismo adscrito al Ministerio de Economía y Competitividad and ‘Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa’ grants PI15/00457 and DTS15/00048 (C.M.); PIE15/00008 and PI15/00146 (J.A.); RETIC Cancer–Instituto de Salud Carlos III RD12/0036/0051 (C.M. and J.A.); 2014SGR740 (J.A.); and Xarxa de Banc de Tumors de Catalunya and Fundació Cellex (C.M.). Investigators at Niguarda Cancer Centers are supported by the grants Terapia Molecolare dei Tumori (A.S.-B. and S.S.) and Dynamic of Tumor Evolution & Therapy (A.S.-B.) from Fondazione Oncologia Niguarda Onlus.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer

  • Siena, S.
  • Sartore-Bianchi, A.
  • García-Carbonero, Rocío|||0000-0002-3342-397X
  • Karthaus, M.
  • Smith, D.
  • Tabernero, Josep|||0000-0002-2495-8139
  • Van Cutsem, E.
  • Guan, X.
  • Boedigheimer, M.
  • Ang, A.
  • Twomey, B.
  • Bach, B. A.
  • Jung, A. S.
  • Bardelli, Alberto
Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue biopsy testing has been the standard for evaluating mutational status; however, plasma testing of cell-free DNA has been shown to be a more sensitive method for detecting clonal evolution. Archival pre- and post-treatment tumor biopsy samples from a phase II study of panitumumab in combination with irinotecan in patients with metastatic colorectal cancer (mCRC) that also collected plasma samples before, during, and after treatment were analyzed for emergence of mutations during/post-treatment by next-generation sequencing and BEAMing. The rate of emergence of tumor tissue RAS mutations was 9.5% by next-generation sequencing (n = 21) and 6.3% by BEAMing (n = 16). Plasma testing of cell-free DNA by BEAMing revealed a mutant RAS emergence rate of 36.7% (n = 39). Exploratory outcomes analysis of plasma samples indicated that patients who had emergent RAS mutations at progression had similar median progression-free survival to those patients who remained wild-type at progression. Serial analysis of plasma samples showed that the first detected emergence of RAS mutations preceded progression by a median of 3.6 months (range, -0.3 to 7.5 months) and that there did not appear to be a mutant RAS allele frequency threshold that could predict near-term outcomes. This first prospective analysis in mCRC showed that serial plasma biopsies are more inclusive than tissue biopsies for evaluating global tumor heterogeneity; however, the clinical utility of plasma testing in mCRC remains to be further explored. NCT00891930.